These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 26692321)

  • 1. Bispecific antibodies and their applications.
    Fan G; Wang Z; Hao M; Li J
    J Hematol Oncol; 2015 Dec; 8():130. PubMed ID: 26692321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The development of bispecific antibodies and their applications in tumor immune escape.
    Zhang X; Yang Y; Fan D; Xiong D
    Exp Hematol Oncol; 2017; 6():12. PubMed ID: 28469973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific antibodies.
    Kontermann RE; Brinkmann U
    Drug Discov Today; 2015 Jul; 20(7):838-47. PubMed ID: 25728220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bispecific antibodies for cancer therapy: A review.
    Krishnamurthy A; Jimeno A
    Pharmacol Ther; 2018 May; 185():122-134. PubMed ID: 29269044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of bispecific antibodies and antibody constructs in oncology and clinical challenges.
    Suurs FV; Lub-de Hooge MN; de Vries EGE; de Groot DJA
    Pharmacol Ther; 2019 Sep; 201():103-119. PubMed ID: 31028837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative molecular formats and therapeutic applications for bispecific antibodies.
    Spiess C; Zhai Q; Carter PJ
    Mol Immunol; 2015 Oct; 67(2 Pt A):95-106. PubMed ID: 25637431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.
    Fournier P; Schirrmacher V
    BioDrugs; 2013 Feb; 27(1):35-53. PubMed ID: 23329400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors.
    Ishiguro T; Sano Y; Komatsu SI; Kamata-Sakurai M; Kaneko A; Kinoshita Y; Shiraiwa H; Azuma Y; Tsunenari T; Kayukawa Y; Sonobe Y; Ono N; Sakata K; Fujii T; Miyazaki Y; Noguchi M; Endo M; Harada A; Frings W; Fujii E; Nanba E; Narita A; Sakamoto A; Wakabayashi T; Konishi H; Segawa H; Igawa T; Tsushima T; Mutoh H; Nishito Y; Takahashi M; Stewart L; ElGabry E; Kawabe Y; Ishigai M; Chiba S; Aoki M; Hattori K; Nezu J
    Sci Transl Med; 2017 Oct; 9(410):. PubMed ID: 28978751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming tumor heterogeneity by ex vivo arming of T cells using multiple bispecific antibodies.
    Park JA; Cheung NV
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy.
    Huang S; van Duijnhoven SMJ; Sijts AJAM; van Elsas A
    J Cancer Res Clin Oncol; 2020 Dec; 146(12):3111-3122. PubMed ID: 32989604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Redirecting T cells to hematological malignancies with bispecific antibodies.
    Velasquez MP; Bonifant CL; Gottschalk S
    Blood; 2018 Jan; 131(1):30-38. PubMed ID: 29118005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bispecific antibodies: design, therapy, perspectives.
    Sedykh SE; Prinz VV; Buneva VN; Nevinsky GA
    Drug Des Devel Ther; 2018; 12():195-208. PubMed ID: 29403265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bispecific Antibody Armed T Cells to Target Cancer Cells.
    Thakur A; Lum LG; Mittal S
    Methods Mol Biol; 2018; 1722():117-126. PubMed ID: 29264802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bispecific antibodies for targeted delivery of anti-cancer therapeutic agents: A review.
    Beishenaliev A; Loke YL; Goh SJ; Geo HN; Mugila M; Misran M; Chung LY; Kiew LV; Roffler S; Teo YY
    J Control Release; 2023 Jul; 359():268-286. PubMed ID: 37244297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry.
    Hong Y; Nam SM; Moon A
    Arch Pharm Res; 2023 Mar; 46(3):131-148. PubMed ID: 36877356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T Cell-Activating Bispecific Antibodies in Cancer Therapy.
    Trabolsi A; Arumov A; Schatz JH
    J Immunol; 2019 Aug; 203(3):585-592. PubMed ID: 31332079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoglobulin Gamma-Like Therapeutic Bispecific Antibody Formats for Tumor Therapy.
    Chen S; Li L; Zhang F; Wang Y; Hu Y; Zhao L
    J Immunol Res; 2019; 2019():4516041. PubMed ID: 30886871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors Affecting the Cancer Immunotherapeutic Efficacy of T Cell Bispecific Antibodies and Strategies for Improvement.
    Long M; Mims AS; Li Z
    Immunol Invest; 2022 Nov; 51(8):2176-2214. PubMed ID: 36259611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of bispecific antibodies in tumor cell and tumor vasculature directed immunotherapy.
    Molema G; Kroesen BJ; Helfrich W; Meijer DK; de Leij LF
    J Control Release; 2000 Feb; 64(1-3):229-39. PubMed ID: 10640660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment.
    Bock AM; Nowakowski GS; Wang Y
    Curr Treat Options Oncol; 2022 Feb; 23(2):155-170. PubMed ID: 35182296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.